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Non-alcoholic fatty liver disease (NAFLD)
is one of the most common causes of
chronic liver disease worldwide (Milic´
and Stimac, 2012). NAFLD affects preva-
lently children and adults with particular
risk factors including genetic susceptibil-
ity and inappropriate lifestyle (i.e., over-
/mal-nutrition and physical inactivity). In
fact, obesity, as well as some traits of
metabolic syndrome, such as insulin resis-
tance and dyslipidemia, are co-morbidities
often associated to the presence of NAFLD
(Vanni et al., 2010). In line with the
increased obesity epidemics, epidemiolog-
ical studies indicate that the estimated
global prevalence of NAFLD ranges from
3–10% depending on age, sex, ethnicity,
and risk factors. Interestingly, in obese
children and adults this prevalence may
raise up to 20–80% (Alisi et al., 2009;
Vernon et al., 2011).
The term of NAFLD defines a series
of hepatic pathologies that include the
relatively benign steatosis that may,
under the pressure of multiple trigger-
ing factors, progress to the more severe
condition of non-alcoholic steatohepatitis
(NASH), characterized by steatosis, necro-
inflammation, and eventually fibrosis
(Brunt, 2010).
The NAFLD development is still
unclear, however, it is now largely accepted
that, beside to the genetic background,
the increased consumption of obesogenic
foods may have a role in the NAFLD
pathogenesis. In particular, diets enriched
in fat and fructose may be steatogenic
in two ways: favoring the occurrence
of systemic insulin resistance closed to
a dangerous accumulation of free fatty
acid (FFA) in the liver; causing depo-
sition of visceral fat and consequent
hepatic insulin resistance responsible for
steatosis development (Tilg and Moschen,
2008). Steatotic liver is susceptible to the
action of next insults that may exacer-
bate steatosis and promote NASH. These
NASH promoters include: imbalance of
production/release of hormones derived
from adipose tissue (adipocytokines) with
consequent necro-inflammation, oxida-
tive stress, activation of specific nuclear
receptors activation, and fibrogenesis
(Malaguarnera et al., 2009). In response
to the systemic insulin resistance, pancre-
atic β-cells increase insulin hypersecretion
accelerating liver fat accumulation and
leading to NAFLD. Recently, it has been
reported that also gut-liver axis may
play a crucial role in this complex net-
work of multiple interactions (Musso
et al., 2010a). In fact, it has been sug-
gested that the diet-dependent increase
of gut microbiota products may influ-
ence intestinal permeability and activate
molecular mechanisms of innate immune
response, acting as possible inductor of
necro-inflammatory lesions and severe
fibrosis in NAFLD (Compare et al., 2012).
The gut microbiota having an exten-
sive cross-talk with the liver represents an
important source of hepatotoxic factors
comprising bacteria and bacterial prod-
ucts. In such as scenario the intestinal
microbiota composition can be affected
and dynamically altered by diet regi-
men, lifestyle, genetic background, antibi-
otic usage, etc (Compare et al., 2012).
The gut microflora exerts various cen-
tral functions, among which fermenta-
tion of dietary components eluding the
digestion and protection against possible
invading pathogens (Othman et al., 2008;
Cani and Delzenne, 2009). Therefore,
the maintenance of the integrity of the
intestinal barrier is of crucial importance
to preserve an healthy gut-liver axis. In
fact, a derangement of the homoeostasis
between bacteria and host and a quali-
tative and quantitative alteration of gut
microflora lead to an increased intestinal
permeability. This promotes bacterial and
endotoxin translocation triggering a pro-
duction of pro-inflammatory molecules
and cytokines and metabolic disorders.
Notably, the intestinal flora, comprised
small intestinal overgrowth (SIBO), has
been found altered in many chronic liver
diseases. On this regard it has been shown
that NAFLD patients have an increased
intestinal permeability and SIBO (Miele
et al., 2009). Several lines of evidence
have shown that NAFLD can be affected
in different way by gut microbiota. From
a side, the microbiota can directly affect
the quantity of calories recovered from
intestinal contents influencing the body
weight possibly preceding the obesity
occurrence. Further, gut microbiota and
related endotoxemia can be implicated
in the development of insulin resistance
involved in NAFLD pathogenesis by var-
ious mechanisms (Cani et al., 2007a,b;
Musso et al., 2010b). Also, the intesti-
nal integrity can be lost by the alteration
of the tight junctions causing an increase
intestinal permeability which leads to bac-
terial translocation and their products
into the systemic circulation, which in
turn reach the liver being correlated to
NAFLD (Miele et al., 2009; De Gottardi
and McCoy, 2011). The gut liver-axis
is the way by which the bacteria and
their potential hepatotoxic products (LPS,
DNA, RNA, etc.) can easily reach the
liver. These microbial compounds can be
generally classified as pathogen-associated
molecular patterns (PAMPs) while the
endogenous products are distinguished
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in damage-associated molecular patterns
(DAMPs). Interestingly, the serum lev-
els of lipopolysaccharide (LPS), one of
most studied PAMPs, are up-regulated in
NASH patients with necro-inflammation
and sever liver damage (Alisi et al., 2010).
The final effect is the activation of the
signaling cascade triggered by specific
immune receptor resulting in the expres-
sion of pro-inflammatory cytokine genes
including tumor necrosis factor (TNF)α
and several interleukins (ILs) that may
exacerbate hepatocyte damage (Figure 1).
The immune system has generated,
along the evolution, a series of specific
pattern recognition receptors (PRRs) com-
prising the Toll-like receptors (TLRs),
which are evolutionary conserved type I
transmembrane glycoproteins. The TLRs
are the immune sensors of PAMPs and/or
DAMPs initiating a signaling cascade lead-
ing to the activation of pro-inflammatory
genes. Notably, each TLR has selectivity
for specific PAMPs or DAMPs and can
also differ from their proper localization
(Alisi et al., 2011). In the liver, TLRs
are expressed in many different cell types
including Kupffer cells, hepatocytes, and
HSCs (Schwabe et al., 2006) being the
TLR4 the specific receptor for the bacterial
endotoxin LPS, which is the key inducer
of pro-inflammatory cytokines (as TNFα,
IL-6, IL-8, IL-12, etc.) through the acti-
vation of the transcription factors NF-kB
(nuclear factor kappa B), AP-1 (activating
protein 1) and also LITAF (LPS-induced
TNFα factor) in the liver (Alisi et al., 2011).
The gut colonization initiates at birth
establishing a dynamic repertoire of gut
microbiota during life that can be altered
in several way giving rise to different
inflammatory conditions possibly lead-
ing to more severe disturbances such as
NAFLD. Many effort have been made
to characterize which bacterial compo-
sition is more healthy to preserve the
host from metabolic disorders and many
progresses have been obtained in ani-
mal model on the study of the role of
gut microbiota and accumulating evi-
dence from human studies are available,
although the examination along the time
of the gastrointestinal bacteria compo-
sition is more difficult to assess. It has
been extensively demonstrated that the
proportion of intestinal microbiota is
dependent on diet regimen. Interestingly,
both in obese human and in mice the
amount of the phyla Bacteroidetes and
Firmicutes, which represent more than
90% of the totality of the gut microbiota,
are altered (the first decreased and the
second increased) (Eckburg et al., 2005).
It has also been shown that a different
balance of Bifidobacterium spp. and fae-
cal Staphylococcus aureus results from the
comparison between normal weight chil-
dren and children which, at long last,
can develop into overweight or obese
subjects, suggesting a possible preced-
ing condition that can foretell the future
obesity occurrence (Kalliomäki et al.,
2008). Further, the fat consumption can
produce a wide amount of lipoprotein-
containing chylomicrons which can guide
the translocation of LPS toward other
organs comprised the liver (Vreugdenhil
et al., 2003). Interestingly, in a study
in human choline-depleted diet it was
described a correlation among the balance
of Gammaproteobacteria/Erysipelotrichi
classes and the occurrence of fatty liver
(Spencer et al., 2011). Besides, in a
murine models fed high-fat diet, the
Bifidobacterium spp. administration deter-
mined an amelioration of the metabolic
panel and a decrease of pro-inflammatory
FIGURE 1 | Gut-derived product effects on liver cells during NAFLD
development. Diets enriched in fat and fructose may disrupt intestinal
barrier, increase intestinal permeability to gut-derived products, and release
of PAMPs and DAMPs into the systemic circulation. PAMPs and DAMPs may
reach liver cells promoting firstly fat accumulation in hepatocytes and
secondly fibrosis and liver cell damage.
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cytokines. Interestingly, the cytokine levels
were augmented in parallel with LPS
amount and inversely to Bifidobacterium
spp. totality (Cani et al., 2007a,b).
Confirming the important correlation
among gut microbiota alteration and
diet, various studies have reported that
an high-fat diet increases the circulat-
ing LPS level amplifying the expansion
of bacteria releasing LPS (Cani et al.,
2007a,b). Moreover, an high-fat diet can
cause a suppression of Eubacterium rectale,
Clostridium coccoides, and Bifidobacterium
spp (Cani and Delzenne, 2009). On the
light of this evidence many probiotics have
been tested in order to restore a balance
in the altered gut microflora. Lactobacillus
and Bifidobacterium spp are the most used
having diversified beneficial results in the
metabolic derangements such ameliora-
tion of dysplidemia, reduction of both
total, LDL and VLDL cholesterol, decrease
of triglycerides which overall are diver-
sified effects depending on the bacterial
species (Xiao et al., 2003; Tannock, 2004;
Larkin et al., 2009). Noteworthy, the alter-
ation of “healthy microbiota” is only one
side of the complex interactions of the
gut-liver axis. The disbiosys is a frac-
tion of the causes leading to metabolic
and gastrointestinal disturbances. All
along, it is emerging a number of stud-
ies correlating the reciprocal interactions
occurring among bacteria, viruses, eukary-
otes, and in turn their communication
with the host immune system. Indeed, the
sequencing project Human Microbiome
Project and the Earth Microbiome Project
would be valid instruments to reach a
wider and comprehensive overall view in
order to better understand the interdepen-
dence between the host microbiota and
the numerous disorders and diseases to
attempt cutting edge therapeutic strategies
(Clemente et al., 2012).
Appropriate dietetic regimens and
physical exercise may improve sim-
ple steatosis, even though this lifestyle
approach is unable to recover NAFLD-
associated liver damage. In fact, it is
widely recognized that lifestyle modifi-
cations combined with a multi-targeted
therapeutic approach against specific
triggering factors could be more effec-
tive than mono-therapeutic approach
in at least paediatric NAFLD (Alisi and
Nobili, 2011). Unfortunately, various
inadequate pharmacological therapies
(e.g., insulin-sensitizers, antioxidants, and
cytoprotective agents) have been devel-
oped over recent years in the attempt of
modifying one or more of the major fac-
tors involved in NAFLD pathogenesis.
Therefore, modifications of gut micro-
biota may be one of the possible objectives
of an efficient multi-target therapy. This
option is supported by several investiga-
tions in animal models studies suggesting
that gut microbiota manipulation with
probiotics reduces intestinal inflammation
and improves the epithelial barrier func-
tion (Iacono et al., 2011). Furthermore,
Loguercio et al. (2005) demonstrated
that a chronic therapy with a probiotic
(VSL#3) in patients affected by several
types of chronic liver diseases, includ-
ing NAFLD may reduce liver damage and
improve serum levels of various biomark-
ers. Interestingly, a pilot study, involving
20 obese children with hypertransami-
nasemia and bright liver at ultrasound,
found that 8 weeks of treatment with
probiotic Lactobacillus rhamnosus strain
GG reduced transaminase levels and
antipeptidoglycan-polysaccharide anti-
bodies, a surrogate test for SIBO
evaluation (Vajro et al., 2011).
In conclusion, as several observations
suggest a potential role of microbiota in
NAFLD development, we believe that pro-
biotics effects on gut flora associated to
their excellent tolerability may represent
promising therapeutic agents to revert
NASH-related liver damage.
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